Evidence map›Paper›PMID 41112857›Full record

ArticleACG case reports journal2025

Infliximab-Induced Organizing Pneumonia Resulting in Persistent Respiratory Impairment.

Khoa Pham, Nicholas Wysham

Abstract readCase Reports
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Organizing pneumonia potentially caused by infliximab in a pediatric patient with ulcerative colitis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Khoa PhamDepartment of Internal Medicine, The Vancouver Clinic and Legacy Salmon Creek Medical Center, Vancouver, WA.
Nicholas WyshamDepartment of Pulmonology, The Vancouver Clinic and Legacy Salmon Creek Medical Center, Vancouver, WA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infliximab is a biologic agent used to treat moderate-to-severe ulcerative colitis by inhibiting the TNF cytokine signaling. Off-target effects of TNF inhibitors include immune suppression and disruption of the tissue repair response. Previous case reports have linked infliximab to several patterns of acute pulmonary toxicity; however, the potential for severe infliximab-induced pneumonitis on long-term respiratory impairment remains largely uncharacterized.

Indexed as

biologicsinflammatory bowel diseaseinfliximabpneumoniaulcerative colitis

Identifiers

PMID41112857
PMCPMC12530310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.